You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL; NORGESTIMATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ETHINYL ESTRADIOL; NORGESTIMATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00236769 ↗ A Study of Efficacy and Safety With the Transdermal Contraceptive System. Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 1997-11-01 The purpose of the study is to evaluate the contraceptive efficacy, safety, cycle control, and compliance with the transdermal contraceptive system.
NCT00254865 ↗ A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2002-08-01 The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other treatment.
NCT00301587 ↗ A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives Withdrawn Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 1969-12-31 The purpose of this study is to compare red blood cell folate levels in women who are taking oral contraceptives with or without folic acid
NCT00320567 ↗ The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Phase 2 1969-12-31 The purpose of this study is to evaluate the effect of norgestimate/ethinyl estradiol on lumbar spine (L1-L4) and total hip bone mineral density (BMD) in pediatric subjects with anorexia nervosa.
NCT00331071 ↗ Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks Completed Boston Collaborative Drug Surveillance Program 2002-04-01 The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with 35 mcg ethinyl estradiol with special attention to duration of use. The study uses data from the PharMetrics Patient-Centric Database and MarketScan database, which are US medical claims databases.
NCT00331071 ↗ Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2002-04-01 The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with 35 mcg ethinyl estradiol with special attention to duration of use. The study uses data from the PharMetrics Patient-Centric Database and MarketScan database, which are US medical claims databases.
NCT00344383 ↗ An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Phase 2 2003-11-01 The purpose of this study is to evaluate the bleeding profile of norgestimate/ethinyl estradiol, an oral contraceptive tablet, given in an extended regimen
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ETHINYL ESTRADIOL; NORGESTIMATE

Condition Name

Condition Name for ETHINYL ESTRADIOL; NORGESTIMATE
Intervention Trials
Contraception 8
Female Contraception 5
Pharmacokinetics 5
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ETHINYL ESTRADIOL; NORGESTIMATE
Intervention Trials
HIV Infections 4
Hepatitis C 3
Acquired Immunodeficiency Syndrome 2
Thromboembolism 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ETHINYL ESTRADIOL; NORGESTIMATE

Trials by Country

Trials by Country for ETHINYL ESTRADIOL; NORGESTIMATE
Location Trials
United States 15
New Zealand 1
Netherlands 1
Thailand 1
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ETHINYL ESTRADIOL; NORGESTIMATE
Location Trials
Texas 4
California 3
Kansas 2
Washington 2
Wisconsin 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ETHINYL ESTRADIOL; NORGESTIMATE

Clinical Trial Phase

Clinical Trial Phase for ETHINYL ESTRADIOL; NORGESTIMATE
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ETHINYL ESTRADIOL; NORGESTIMATE
Clinical Trial Phase Trials
Completed 24
Unknown status 3
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ETHINYL ESTRADIOL; NORGESTIMATE

Sponsor Name

Sponsor Name for ETHINYL ESTRADIOL; NORGESTIMATE
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 9
Bristol-Myers Squibb 5
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ETHINYL ESTRADIOL; NORGESTIMATE
Sponsor Trials
Industry 31
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.